However, in neuroendocrine tumors (NETs), SSTR2 is often significantly overexpressed, making it a highly attractive target for both diagnostic imaging and peptide receptor radionuclide therapy (PRRT) through theranostic approaches. This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.